Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Bio-Rad launches QC online learning center

April 2024—Bio-Rad Laboratories has launched its online Quality Controls Learning Center, a free resource designed to provide laboratories with the educational resources needed to maintain quality control patient test results. The site provides a library of articles and best practices on quality control process and design, laboratory management, quality control data management, quality control troubleshooting and solutions, and the benefits of independent quality control.

Sekisui gets EUA for Osom flu, SARS-CoV-2 test

April 2024—Sekisui Diagnostics has received emergency use authorization for its Osom Flu SARS-CoV-2 Combo test for use in professional and home testing settings. The lateral flow immunochromatographic assay is intended for the qualitative detection and differentiation of influenza A and B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen. The test is for in vitro diagnostic use.

SpotFire R/ST panel gets 510(k) clearance, CLIA waiver

April 2024—BioMérieux has received FDA 510(k) clearance and CLIA waiver approval for the BioFire SpotFire Respiratory/Sore Throat (R/ST) panel. The multiplex PCR test is for the detection and identification of nucleic acids from up to 15 of the most common bacteria, viruses, and viral subtypes responsible for respiratory or sore throat infections. Samples can be taken from a nasopharyngeal swab when a respiratory tract infection is suspected or from a throat swab in case of a pharyngitis syndrome. Results are available in about 15 minutes on the BioFire SpotFire system.

Verichem releases microprotein reference materials

April 2024—Verichem Laboratories offers a multilevel set of clinical reference materials intended for the calibration verification of clinical systems testing for total protein and albumin in urine and cerebrospinal fluid samples. The liquid-stable and ready-to-use materials are suitable for use with turbidimetric and colorimetric test methods and incorporate human protein components.

Bayer, Thermo Fisher to develop NGS CDx assays

April 2024—Bayer and Thermo Fisher Scientific announced that they will develop next-generation sequencing–based companion diagnostic assays to help identify patients who may benefit from Bayer’s precision cancer therapies. The assays will be developed using Thermo Fisher’s Oncomine Dx Express test on the Ion Torrent Genexus Dx system. The Genexus Dx instrument and Oncomine Dx Express test are CE-IVD marked and only available in countries that accept the CE mark.

De novo classification granted for ADAMTS13 activity test

April 2024—Technoclone and its distributor in the United States, DiaPharma Group, announced that the FDA has granted de novo classification for the Technozym ADAMTS13 Activity ELISA. The assay is intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma and indicated for use in conjunction with other clinical and laboratory findings as an aid in diagnosing thrombotic thrombocytopenic purpura in adult and pediatric patients being evaluated for thrombotic microangiopathy.

Bio-Rad gets My Green Lab certification

April 2024—Bio-Rad Laboratories announced it received My Green Lab certification for its R&D facilities in Irvine, Calif. It has been certified at My Green Lab’s highest rating, green, which reflects the percentage of possible green lab best practices that have been adopted and the extent to which they have been adopted by the lab.

Bio-Rad publishes third workbook in QC series

March 2024—Bio-Rad Laboratories has published the third workbook in a P.A.C.E.-approved series designed to provide lab professionals with the training and education needed to maintain reliable test results. “Quality Control Process Optimization with Cost of Quality Application” focuses on a practical approach of cost of quality to the laboratory workflow process of quality control. After using the workbook, laboratorians will be able to construct a basis worksheet to calculate the failure costs of a selected failed laboratory process.

Agilent, Incyte collaborate to develop CDx

March 2024—Agilent Technologies announced an agreement with Incyte to develop companion diagnostics in hematology and oncology. The agreement enables Agilent to continue to expand its companion diagnostics portfolio with novel biomarkers and Incyte to leverage Agilent’s expertise in IVD assay development, global regulatory approvals, and commercialization to support clinical trials as well as the potential registration and commercialization of companion diagnostics in the United States and Europe.

Innovative Lab Solutions welcomes VP of solutions

March 2024—Innovative Lab Solutions announced the appointment of Bridget Ketron as its vice president of solutions. With a focus on enhancing efficiency, boosting cash collections, and ensuring compliance, Ketron will play a key role in driving the company’s growth and strategic partnerships.

MARKETPLACE

TRENDING